To our knowledge, this systematic review and meta‐analysis is the first to comprehensively summarize observational studies that have adjusted for covariates and examined the association between the use of GLP‐1 receptor agonists before admission or diagnosis and the risk of mortality in patients with COVID‐19 and diabetes. This evidence concerns the gene GLP1R and COVID-19.